Author: Anonymous

A regulatory reviewer is assessing a clinical study report (CSR) submitted as part of Module 5 of a Common Technical Document (CTD) for a generic medicine application. During the review, the assessor notes the following issues:The report lacks a clear and standardised structure (e.g., missing synopsis, inconsistent section headings).Key sections such as patient disposition, efficacy evaluation, and safety results are incomplete or poorly organised Appendices (e.g., protocols, statistical analysis plans) are missing or not properly referenced.The sponsor argues that the report is acceptable because the study was conducted in compliance with Good Clinical Practice. Which guideline is most directly relevant for addressing the deficiencies identified of this clinical study report?

A CTD application for a generic medicine with clinical data includes data supporting two different indications. In Module 5, the applicant provides:• A single, large, combined clinical study report file containing all studies across both indications,• No separation into synopsis, main body, and appendices,• Appendices embedded inconsistently within the document rather than structured according to recognised standards. During lifecycle management, one study needs to be updated due to revised statistical analyses. It is, however, difficult to replace only the affected sections. Which of the following best describes the key deficiencies in relation to CTD granularity of the application?

The Sponsor receives notification from a clinical investigator of a fatal adverse event suspected to be related to one of its authorised medicines. The event is not consistent with the known safety profile described in the current product information and is therefore considered unexpected. According to pharmacovigilance reporting requirements, what is the appropriate timeframe for submitting this report to the relevant regulatory authority from the date of first awareness?

When compiling the clinical sections of a Common Technical Document (CTD) for a generic medicine application, which has a bioequivalence study in support of efficacy, a regulatory scientist must consult two distinct types of guidelines. Which of the following best describes these two types of guidelines?

A formulation of a complementary medicine contains well-established herbal ingredients that are recognised within a defined therapeutic discipline. The product adheres to all specified limits for dosage, indications, and route of administration, and does not include any restricted or higher-risk substances. Compliance with quality standards, including Good Manufacturing Practice (GMP), is demonstrated and all claims fall within those permitted for low-risk products. Which of the following is the most appropriate course of action?

Which of the following statements correctly describe the requirements for conducting clinical trials in South Africa and the data needed for medicine registration?

In a controlled clinical study evaluating a new therapeutic intervention, measures are implemented to minimise bias by concealing treatment allocation. Both the individuals receiving the intervention and the clinical staff responsible for administering treatments and assessing outcomes are kept unaware of which intervention each participant receives. Which of the following best describes this study design?

Your patient has LTB. Your appropriate action would be to deliver racemic epinephrine and intubate after 1 dose.

A fungal infection spreading through crops can best be controlled by:

Which structure forms the main body of multicellular fungi?